Who Paid My Doc
Abraham Rothman
Pediatric Cardiology Las Vegas, NV Medical Doctor
NPI 1730162074 CMS profile 33662
3131 La Canada St Ste 230, Las Vegas, NV 89169
General payments
$174,678
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$101,519
Through program year 2025, Abraham Rothman of Las Vegas, NV is reported in the CMS Open Payments database as having received $174,678 across 156 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $101,519 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 98th percentile of Pediatric Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $66,761 | 39 | |
| 2024 | General | $83,529 | 59 | |
| 2023 | General | $14,162 | 18 | |
| 2022 | General | $7,187 | 17 | |
| 2021 | General | $2,812 | 10 | |
| 2020 | General | $40 | 2 | |
| 2019 | General | $187 | 11 |
Beside peers
- Abraham Rothman
- Pediatric Cardiology median
- Middle half of Pediatric Cardiology
- National median
In program year 2025, general payments to Abraham Rothman were reported at $66,761. Among 1,168 Pediatric Cardiology profiles paid that year, the median was $146 and the middle half received between $47 and $670.
Show as a table
| Year | Abraham Rothman | Pediatric Cardiology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $187 | $124 | $35–$516 | $163 |
| 2020 | $40 | $70 | $23–$326 | $114 |
| 2021 | $2,812 | $112 | $27–$445 | $132 |
| 2022 | $7,187 | $129 | $36–$680 | $149 |
| 2023 | $14,162 | $149 | $38–$826 | $160 |
| 2024 | $83,529 | $131 | $37–$652 | $164 |
| 2025 | $66,761 | $146 | $47–$670 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 8 drugsPart D claims
191
Drug cost
$1,732,775
Branded share of claims
53.4%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Uptravi Selexipag | Brand | 29 | $680,726 | |
| Opsumit Macitentan | Brand | 37 | $448,349 | |
| Orenitram Er Treprostinil Diolamine | Brand | 24 | $354,909 | |
| Adempas Riociguat | Brand | 12 | $163,674 | |
| Ambrisentan | Generic | 30 | $58,250 | |
| Tadalafil | Generic | 11 | $24,961 | |
| Sildenafil Citrate | Generic | 35 | $1,801 | |
| Furosemide | Generic | 13 | $105 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 21 billing codesPaid by Medicare
$7,027
Medicare patients
19
Services billed
138
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Payments and prescribing
3 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| WINREVAIR |
|
$53 | — | — |
| OPSUMIT |
|
$48 | 37 | — |
| UPTRAVI |
|
$48 | 29 | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
Records
156 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Pediatric Cardiology in Nevada
Alvaro Galindo
Pediatric Cardiology · Las Vegas, NV
Brittany Navarre
Pediatric Cardiology · Las Vegas, NV
Austin Mercadante
Pediatric Cardiology · Las Vegas, NV
Ricardo Samson
Pediatric Cardiology · Las Vegas, NV
John Alexander
Pediatric Cardiology · Las Vegas, NV
Carlos Luna
Pediatric Cardiology · Las Vegas, NV
Related records
Pediatric Cardiology in Nevada
Practitioners in the same specialty and state, ranked by reported value.
All Pediatric Cardiology
Everyone recorded under this specialty, nationwide.
Doctors in Nevada
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.